Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis.

PloS one - 19 Apr 2011

Craig-Schapiro Rebecca, Kuhn Max, Xiong Chengjie, Pickering Eve H, Liu Jingxia, Misko Thomas P, Perrin Richard J, Bales Kelly R, Soares Holly, Fagan Anne M, Holtzman David M

Abstract excerpt

BACKGROUND: Clinicopathological studies suggest that Alzheimer's disease (AD) pathology begins ∼10-15 years before the resulting cognitive impairment draws medical attention. Biomarkers that can detect AD pathology in its early stages and predict dementia onset would, therefore, be invaluable for patient care and efficient clinical trial design. We utilized a targeted proteomics approach to discover novel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Artificial Intelligence

Share to Cognition Disorders

Share to Demography

Share to Immunoassay

Share to Proportional Hazards Models

Share to ROC Curve

Source

Open in PubMed Open full text

Identifiers

PMID: 21526197
DOI: 10.1371/journal.pone.0018850
PMCID: PMC3079734

Genes

FAS
MIF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis.PMID 21526197Read ↗

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s diseaseSemantic proximity Read ↗

Identification of Novel Biomarkers for Alzheimer’s Disease and Related Dementias Using Unbiased Plasma ProteomicsSemantic proximity Read ↗

Blood-Based Biomarkers in Alzheimer's Disease: Advancing Non-Invasive Diagnostics and PrognosticsSemantic proximity Read ↗

High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed dementia cohortSemantic proximity Read ↗

Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine ApproachSemantic proximity Read ↗

Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's diseaseSemantic proximity Read ↗

A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimer's Disease.Semantic proximity Read ↗

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular eventsSemantic proximity Read ↗

A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer’s disease pathologySemantic proximity Read ↗

Novel Plasma Protein Biomarkers: A Time-Dependent predictive model for Alzheimer's DiseaseSemantic proximity Read ↗

Multiplex cerebrospinal fluid proteomics identifies biomarkers for diagnosis and prediction of Alzheimer’s diseaseSemantic proximity Read ↗

Emerging Biomarkers for Early Detection of Alzheimer’s Disease: A Systematic ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.